Telehealth providers in Arkansas

Verified telehealth providers serving Arkansas

Telehealth prescribing rules in Arkansas

The Arkansas Telemedicine Act (Ark. Code 17-80-401 through 17-80-407, amended by Acts 767, 829, and 1112 of 2021) defines telemedicine to include store-and-forward technology and remote patient monitoring, and section 17-80-403 bars a distant-site professional from using telemedicine with an Arkansas patient unless a professional relationship exists. Section 17-80-402(4) lists the ways that relationship can exist: a prior in-person exam, personal knowledge through an ongoing relationship, treatment in consultation with or on referral from a professional who has a relationship with the patient, an on-call or cross-coverage arrangement, circumstances defined by Arkansas State Medical Board rule, or, added in 2021, an Arkansas-licensed professional who has access to the patient's health record and uses any technology the professional deems appropriate, including the telephone, to diagnose, treat, and if clinically appropriate prescribe a noncontrolled drug. The same subdivision says a health record may be created with the use of telemedicine if the professional meets the in-person standard of care, and the Medical Board's rule (17 CAR 140-202(b)(8)) mirrors this, so the 2021 amendments did broaden relationship formation: a telephone or video evaluation that builds a proper health record can support a first non-controlled prescription. Section 17-80-403(c) still excludes a relationship established only by an internet questionnaire, email, patient-generated medical history, text messaging, fax, or any combination of them, and the Medical Board's telemedicine rule (17 CAR 140-3201) adds that a patient completing a medical history online and forwarding it is not sufficient and does not count as store-and-forward, so a first GLP-1 or compounded peptide prescription cannot lawfully follow a questionnaire-only asynchronous intake. Once the relationship exists, follow-up care may use asynchronous tools if the standard of care is met. Section 17-80-404 and 17 CAR 140-3201 require the treating professional to be licensed in Arkansas. [2] [3] [4] [8] [9]

Compounded GLP-1 access in Arkansas

Compounded semaglutide and tirzepatide are limited to documented patient-specific needs after the FDA shortage allowances ended in 2025, and Arkansas's own compounding regulation separately bars routine copies of commercially available drugs. Because Arkansas law does not let an online questionnaire alone establish the patient relationship, Arkansas patients should expect a live evaluation (in person, by video, or by telephone backed by a health record) before a first GLP-1 prescription, and should confirm the dispensing pharmacy holds an Arkansas license with an Arkansas-licensed pharmacist in charge. [3] [5] [7] [13]

Research use only sellers in Arkansas

Only Arkansas-licensed pharmacies may dispense prescription drugs to Arkansas patients, including out-of-state pharmacies licensed under Ark. Code 17-92-401. "Research use only" peptides sold for human injection are unapproved new drugs under federal law regardless of labeling, are not dispensed by a pharmacist, and carry no Arkansas licensing protections. The Arkansas Food, Drug, and Cosmetic Act (Ark. Code 20-56-201 and following) has no separate new-drug approval section, so the unapproved-drug prohibition comes from federal law; the state act does prohibit selling a misbranded drug (Ark. Code 20-56-215) and treats a drug as misbranded unless its labeling bears adequate directions for use and adequate warnings (Ark. Code 20-56-211). [5] [10] [11] [14]